Asthma
Respiratory 10 original drugsMarket Leaders
Phase 3 Readouts Pro
12 active Phase 3 trials with confidence-graded completion dates.
Q2 2027
TQC2731 injection
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Estimated · stale NCT06829784
Unlock 9 more readouts with confidence-graded estimates
Upgrade to Pro Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Treatments by Mechanism
Top 12 mechanisms across 94 industry trials with a known mechanism of action.
Interleukin-4 Receptor alpha Antagonist
12 trials 3 active 2 sponsors
Interleukin-5 Receptor alpha-directed Cytolytic Antibody
20 trials 2 active 2 sponsors
Interleukin-5 Antagonist
15 trials 1 active 3 sponsors
Glucocorticoid receptor
12 trials 3 sponsors
Anti-IgE
12 trials 5 sponsors
Corticosteroid
8 trials 4 sponsors
Beta-2 adrenergic receptor/Glucocorticoid receptor
7 trials 5 sponsors
Interleukin-13 Antagonist
2 trials 1 sponsor
H1 receptor
2 trials 1 sponsor
M3 muscarinic receptor/beta 2-adrenoceptor
2 trials 1 sponsor
Glucocorticoid receptor/beta 2-adrenergic receptor
1 trials 1 sponsor
Adenosine Receptor Agonist
1 trials 1 sponsor
MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.
Clinical Pipeline by Phase
884 industry-sponsored trials across 189 sponsors
Showing 67 of 67 trials
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Regeneron | dupilumab | Interleukin-4 Receptor alpha Antagonist [EPC] | RECRUITING | 2026-12-31 | NCT06572228 |
| AstraZeneca | Benralizumab | Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC] | ACTIVE NOT RECRUITING | 2026-10-19 | NCT03953300 |
| Sanofi | Dupilumab | Interleukin-4 Receptor alpha Antagonist [EPC] | ACTIVE NOT RECRUITING | 2027-03-16 | NCT05097287 |
| AstraZeneca | Albuterol and budesonide inhalation aerosol | — | ACTIVE NOT RECRUITING | 2027-03-31 | NCT06422689 |
| GSK | Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate | — | ACTIVE NOT RECRUITING | 2025-07-28 | NCT06372496 |
| GSK | Mepolizumab | Interleukin-5 Antagonist [EPC] | ACTIVE NOT RECRUITING | 2025-01-31 | NCT06041386 |
| AstraZeneca | Tezepelumab | — | COMPLETED | 2025-10-01 | NCT05329194 |
| Sanofi | Dupilumab | Interleukin-4 Receptor alpha Antagonist [EPC] | COMPLETED | 2024-10-16 | NCT04998604 |
| AstraZeneca | — | — | COMPLETED | 2024-09-03 | NCT05440097 |
| AstraZeneca | — | — | COMPLETED | 2024-07-19 | NCT05552508 |
| Orion Corporation, Orion Pharma | — | — | COMPLETED | 2024-04-24 | NCT04869384 |
| GSK | Mepolizumab | Interleukin-5 Antagonist [EPC] | COMPLETED | 2023-10-28 | NCT04276233 |
| Sanofi | SAR231893 | — | COMPLETED | 2023-10-03 | NCT04502862 |
| Regeneron | dupilumab | Interleukin-4 Receptor alpha Antagonist [EPC] | COMPLETED | 2023-07-15 | NCT04203797 |
| AstraZeneca | Benralizumab | Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC] | COMPLETED | 2023-07-01 | NCT05384938 |
| Orion Corporation, Orion Pharma | Buventol® Easyhaler® 200 µg/inhalation dmDPI | — | COMPLETED | 2023-06-30 | NCT05084222 |
| Sanofi | Dupilumab | Interleukin-4 Receptor alpha Antagonist [EPC] | COMPLETED | 2023-06-26 | NCT04400318 |
| AstraZeneca | Symbicort® | — | COMPLETED | 2023-01-31 | NCT04159519 |
| AstraZeneca | — | — | COMPLETED | 2022-12-16 | NCT03924635 |
| Teva Branded Pharmaceutical Products R&D, Inc. | Fluticasone propionate/salmeterol (FS) | — | COMPLETED | 2022-03-04 | NCT04677959 |
| Teva Branded Pharmaceutical Products R&D, Inc. | Albuterol eMDPI DS | — | COMPLETED | 2021-10-04 | NCT03890666 |
| GSK | — | — | COMPLETED | 2021-07-08 | NCT04813354 |
| Intech Biopharm Ltd. | Budesonide 200 microgram/Puff, HFA MDI | — | COMPLETED | 2021-05-09 | NCT05152355 |
| GSK | Fluticasone furoate | Glucocorticoid receptor | COMPLETED | 2021-04-09 | NCT02889809 |
| Amphastar Pharmaceuticals, Inc. | — | — | COMPLETED | 2019-12-20 | NCT04207840 |
| GSK | ACT guided Routine Treatment | — | COMPLETED | 2019-08-09 | NCT02868281 |
| GSK | RELVAR/BREO | — | COMPLETED | 2019-01-24 | NCT03380429 |
| GSK | Placebo DPI | — | COMPLETED | 2018-12-07 | NCT03478657 |
| PharmEvo Pvt Ltd | Montelukast | — | COMPLETED | 2017-12-30 | NCT03096327 |
| Roche | FP | — | COMPLETED | 2017-07-10 | NCT02537691 |
| Asthma Management Systems | Dulera | Glucocorticoid receptor/beta 2-adrenergic receptor | COMPLETED | 2017-07-01 | NCT02045875 |
| GSK | Mepolizumab 100mg SC | — | COMPLETED | 2017-05-31 | NCT02654145 |
| GSK | Fluticasone furoate/ Vilanterol 100 mcg/25 mcg | — | COMPLETED | 2017-02-03 | NCT02730351 |
| GSK | — | — | COMPLETED | 2016-12-15 | NCT02794480 |
| Organon and Co | Mometasone Furoate/Formoterol MDI 100/5 mcg | — | COMPLETED | 2016-11-30 | NCT01471340 |
| Menarini International Operations Luxembourg SA | Bilastine 20mg | — | COMPLETED | 2016-11-24 | NCT02761252 |
| Hanmi Pharmaceutical Company Limited | one-way education | — | COMPLETED | 2016-09-01 | NCT03110874 |
| GSK | FP/ SLM HFA MDI 50/25 mcg | — | COMPLETED | 2016-06-01 | NCT02113436 |
| Roche | Omalizumab | Anti-IgE [EPC] | COMPLETED | 2016-03-31 | NCT01922037 |
| GSK | Placebo ELLIPTA inhaler | — | COMPLETED | 2016-02-04 | NCT02586506 |
| GSK | NEUMOTEROL 400 (BFF 400/12 mcg) single capsule inhaler | — | COMPLETED | 2015-12-11 | NCT02233803 |
| GSK | ADVAIR 100/50mcg | — | COMPLETED | 2015-11-01 | NCT01462344 |
| GSK | — | — | COMPLETED | 2015-08-20 | NCT02416180 |
| GSK | ADVAIR 100/50mcg | — | COMPLETED | 2015-06-23 | NCT01475721 |
| GSK | — | — | COMPLETED | 2015-05 | NCT02195284 |
| Eisai Co., Ltd. | lysozyme 90 mg | — | COMPLETED | 2013-12 | NCT01715493 |
| Roche | Omalizumab | Anti-IgE [EPC] | COMPLETED | 2013-08 | NCT01125748 |
| Cornerstone Therapeutics Inc. | Zileuton extended release | — | COMPLETED | 2013-06 | NCT01805687 |
| Mundipharma AB | Mannitol challenge test & reversibility test | — | COMPLETED | 2012-04 | NCT01449123 |
| Novartis | omalizumab at a dose of 0.016mg/kg/IU/mL | — | COMPLETED | 2011-11 | NCT00670930 |
| GSK | FLOVENT™ DISKUS™ 100 mcg BID | — | COMPLETED | 2010-12 | NCT01192178 |
| Grünenthal Colombiana S.A. | Beclomethasone | — | COMPLETED | 2010-12 | NCT01333800 |
| AstraZeneca | Symbicort (Budesonide/Formoterol) | — | COMPLETED | 2010-08 | NCT00939341 |
| AstraZeneca | Ciclesonide | Glucocorticoid receptor | COMPLETED | 2010-07 | NCT00826969 |
| GSK | — | — | COMPLETED | 2010-04 | NCT00858286 |
| Novartis | Omalizumab | Anti-IgE [EPC] | COMPLETED | 2010-03 | NCT00870584 |
| Astellas Pharma Inc | Regadenoson | Adenosine Receptor Agonist [EPC] | COMPLETED | 2009-10 | NCT00862641 |
| AstraZeneca | Budesonide / formoterol fumarate (SYMBICORT) | — | COMPLETED | 2009-09 | NCT00702325 |
| Roche | Cohort I | — | COMPLETED | 2009-04 | NCT00777764 |
| Novartis | Xolair | Anti-IgE [EPC] | COMPLETED | 2009-01 | NCT00624832 |
| AstraZeneca | Symbicort Turbuhaler 160/4.5 | — | COMPLETED | — | NCT00576316 |
| Chiesi Farmaceutici S.p.A. | Administration via pressurized metered dose inhaler (pMDI) | — | TERMINATED | 2024-04-16 | NCT05018598 |
| Roche | Omalizumab | Anti-IgE [EPC] | TERMINATED | 2021-10-18 | NCT04195958 |
| Teva Branded Pharmaceutical Products R&D, Inc. | Reslizumab | Interleukin-5 Antagonist [EPC] | TERMINATED | 2017-05-24 | NCT02937168 |
| Mundipharma Korea Ltd | Fluticasone/Formoterol | — | TERMINATED | 2017-04-06 | NCT02491970 |
| GSK | Fluticasone Furoate/Vilanterol | — | WITHDRAWN | 2019-05-29 | NCT03363191 |
| Novartis | Foradil Combi (Formoterol-budesonide) | — | WITHDRAWN | 2010-07 | NCT00997477 |
Showing 100 of 258 trials (top 100 by completion date — export for full list)
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Teva Branded Pharmaceutical Products R&D LLC | Fp/ABS | — | RECRUITING | 2026-05-31 | NCT06664619 |
| AstraZeneca | — | — | RECRUITING | 2026-10-30 | NCT06471257 |
| Teva Branded Pharmaceutical Products R&D LLC | TEV-56248 | — | RECRUITING | 2026-10-31 | NCT06052267 |
| GSK | FF/UMEC/VI | — | RECRUITING | 2027-01-15 | NCT05757102 |
| Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 610 | — | RECRUITING | 2027-02 | NCT06323213 |
| Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | TQC2731 injection | — | RECRUITING | 2027-06 | NCT06829784 |
| AstraZeneca | Tezepelumab | — | RECRUITING | 2027-08-07 | NCT07363642 |
| AstraZeneca | — | — | RECRUITING | 2027-10-13 | NCT06307665 |
| Shanghai Mabgeek Biotech.Co.Ltd | MG-K10/Placebo | — | RECRUITING | 2027-11-15 | NCT06837922 |
| GSK | Depemokimab | — | RECRUITING | 2027-12-08 | NCT06979323 |
| Guangdong Hengrui Pharmaceutical Co., Ltd | SHR-1905 Injection | — | RECRUITING | 2028-01 | NCT07098403 |
| Novartis | QMF149 | — | RECRUITING | 2028-02-01 | NCT05562466 |
| AstraZeneca | Tezepelumab | — | RECRUITING | 2028-05-31 | NCT06023589 |
| Generate Biomedicines | GB-0895 | — | RECRUITING | 2028-12 | NCT07276724 |
| Sanofi | Dupilumab | Interleukin-4 Receptor alpha Antagonist [EPC] | RECRUITING | 2028-12-21 | NCT06191315 |
| CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | CM326 | — | RECRUITING | 2028-12-31 | NCT07372287 |
| Generate Biomedicines | GB-0895 | — | RECRUITING | 2029-01 | NCT07359846 |
| AstraZeneca | Benralizumab | Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC] | RECRUITING | 2030-05-05 | NCT05692180 |
| CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | CM310 | — | RECRUITING | 2032-05 | NCT05761028 |
| AstraZeneca | — | — | ACTIVE NOT RECRUITING | 2027-06-25 | NCT06473779 |
| AstraZeneca | BDA MDI HFO 160/180 μg | — | ACTIVE NOT RECRUITING | 2026-03-03 | NCT06502366 |
| Inmunotek S.L. | 3,000 MM09 | — | NOT YET RECRUITING | 2026-06-01 | NCT05641272 |
| Chiesi Farmaceutici S.p.A. | Experimental: Participant Group CHF 5993 pMDI HFA-152a | — | NOT YET RECRUITING | 2028-10-17 | NCT07546981 |
| Qilu Pharmaceutical Co., Ltd. | tezepelumab (Arm1&Arm2) | — | NOT YET RECRUITING | 2028-12 | NCT07302516 |
| Novartis | QVM149 | — | NOT YET RECRUITING | 2028-12-21 | NCT05776927 |
| AstraZeneca | Benralizumab | Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC] | NOT YET RECRUITING | 2029-12-28 | NCT07444567 |
| GSK | Depemokimab | — | NOT YET RECRUITING | 2030-07-01 | NCT07456033 |
| GSK | GSK3511294 (Depemokimab) | — | COMPLETED | 2025-09-14 | NCT04718389 |
| GSK | Salbutamol HFA-134a | — | COMPLETED | 2025-09-02 | NCT06261957 |
| GSK | GSK3511294 (Depemokimab) | — | COMPLETED | 2025-05-19 | NCT05243680 |
| Sanofi | Dupilumab (SAR231893/REGN668) | — | COMPLETED | 2025-04-01 | NCT03560466 |
| AstraZeneca | BGF MDI 320/28.8/9.6 μg | — | COMPLETED | 2025-03-21 | NCT04609878 |
| AstraZeneca | BGF MDI 320/28.8/9.6 μg | — | COMPLETED | 2025-03-20 | NCT04609904 |
| AstraZeneca | BFF MDI 320/9.6 μg | — | COMPLETED | 2025-02-26 | NCT05202262 |
| Chiesi Farmaceutici S.p.A. | CHF5993 200/6/12.5 μg pMDI HFA-152a | — | COMPLETED | 2025-02-18 | NCT06264674 |
| AstraZeneca | BFF MDI 160/9.6 μg BID (320/19.2μg/day) | — | COMPLETED | 2024-11-19 | NCT05755906 |
| AstraZeneca | — | — | COMPLETED | 2024-11-18 | NCT05555290 |
| Cipla Ltd. | Albuterol Sulfate Inhalation Aerosol (90 mcg per actuation) | — | COMPLETED | 2024-09-16 | NCT06154304 |
| AstraZeneca | Tezepelumab | — | COMPLETED | 2024-09-09 | NCT05274815 |
| Bond Avillion 2 Development LP | BDA MDI | — | COMPLETED | 2024-08-22 | NCT05505734 |
| GSK | FF/VI | — | COMPLETED | 2024-08-05 | NCT04937387 |
| Chiesi Farmaceutici S.p.A. | Beclomethasone Dipropionate/Formoterol Fumarate | — | COMPLETED | 2024-06-24 | NCT05292586 |
| AstraZeneca | Experimental: Tezepelumab | — | COMPLETED | 2024-05-24 | NCT03927157 |
| GSK | GSK3511294 | — | COMPLETED | 2024-04-11 | NCT04718103 |
| GSK | GSK3511294 (Depemokimab) | — | COMPLETED | 2023-11-21 | NCT04719832 |
| AstraZeneca | HFA MDI | — | COMPLETED | 2023-08-21 | NCT05850494 |
| Cipla Ltd. | Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg | — | COMPLETED | 2023-08-15 | NCT05322707 |
| Chiesi Farmaceutici S.p.A. | Beclomethasone dipropionate 100 µg / Formoterol fumarate 6 µg (Inhaler A) | — | COMPLETED | 2023-02-01 | NCT04886999 |
| AstraZeneca | Benralizumab | Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC] | COMPLETED | 2023-01-30 | NCT03186209 |
| Cinnagen | Omalizumab (CinnaGen) | — | COMPLETED | 2023-01-15 | NCT05813470 |
| GSK | Mepolizumab 100 milligrams | — | COMPLETED | 2022-09-07 | NCT03562195 |
| Sanofi | Dupilumab SAR231893 | — | COMPLETED | 2022-05-21 | NCT03782532 |
| ALK-Abelló A/S | HDM SLIT-tablet | — | COMPLETED | 2022-05-18 | NCT03654976 |
| GSK | FF/VI via ELLIPTA DPI | — | COMPLETED | 2022-03-21 | NCT03248128 |
| AstraZeneca | Tezepelumab | — | COMPLETED | 2022-03-21 | NCT05062759 |
| Sanofi | Dupilumab SAR231893 (REGN668) | — | COMPLETED | 2022-02-18 | NCT03620747 |
| Chiesi Farmaceutici S.p.A. | Foster 100/6mg NEXThaler | — | COMPLETED | 2021-12-28 | NCT03453112 |
| AstraZeneca | Tezepelumab | — | COMPLETED | 2021-10-26 | NCT03706079 |
| Bond Avillion 2 Development LP | Albuterol sulfate metered-dose inhaler 180 μg | — | COMPLETED | 2021-08-19 | NCT03769090 |
| Respirent Pharmaceuticals Co Ltd. | Fluticasone propionate 100 mcg/blister oral inhalation powder/Respirent Pharmaceuticals | — | COMPLETED | 2021-08-13 | NCT04665895 |
| Bond Avillion 2 Development LP | Budesonide metered dose inhaler / BD MDI 160 µg | — | COMPLETED | 2021-07-20 | NCT03847896 |
| Actavis Inc. | Fluticasone propionate pressurized metered dose inhaler | — | COMPLETED | 2021-05-28 | NCT03879837 |
| AstraZeneca | Benralizumab | Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC] | COMPLETED | 2021-04-16 | NCT03557307 |
| AstraZeneca | Biological: Experimental: Tezepelumab | — | COMPLETED | 2021-03-18 | NCT04048343 |
| AstraZeneca | Tezepelumab | — | COMPLETED | 2020-09-25 | NCT03406078 |
| AstraZeneca | Experimental: Tezepelumab | — | COMPLETED | 2020-09-08 | NCT03347279 |
| AB Science | Masitinib | — | COMPLETED | 2020-09 | NCT03771040 |
| Sanofi | Dupilumab | Interleukin-4 Receptor alpha Antagonist [EPC] | COMPLETED | 2020-08-26 | NCT02948959 |
| AstraZeneca | Benralizumab | Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC] | COMPLETED | 2020-06-18 | NCT02808819 |
| AstraZeneca | Tezepelumab (APFS) | — | COMPLETED | 2020-06-05 | NCT03968978 |
| Cipla Ltd. | Fluticasone propionate/salmeterol 100/50 µg | — | COMPLETED | 2019-12-03 | NCT03394989 |
| AB Science | Masitinib | — | COMPLETED | 2019-11 | NCT01449162 |
| Actavis Inc. | Fluticasone Propionate and Salmeterol Inhalation Powder | — | COMPLETED | 2019-10-26 | NCT03756883 |
| AstraZeneca | Benralizumab | Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC] | COMPLETED | 2019-10-22 | NCT02821416 |
| Novartis | QAW039 | — | COMPLETED | 2019-10-21 | NCT02555683 |
| Sanofi | Dupilumab | Interleukin-4 Receptor alpha Antagonist [EPC] | COMPLETED | 2019-10-11 | NCT02134028 |
| AstraZeneca | Benralizumab (Medi-563) | — | COMPLETED | 2019-09-25 | NCT03170271 |
| Pearl Therapeutics, Inc. | GP MDI 28.8 μg | — | COMPLETED | 2019-09-12 | NCT03358147 |
| Aurobindo Pharma Ltd | Test Product | — | COMPLETED | 2019-08-29 | NCT04051710 |
| Respirent Pharmaceuticals Co Ltd. | Fluticasone Propionate 100 mcg and Salmeterol 50 mcg inhalation Powder/Respirent Pharmaceuticals | — | COMPLETED | 2019-08-02 | NCT03676413 |
| GSK | Mepolizumab 100mg | — | COMPLETED | 2019-07-24 | NCT02555371 |
| Novartis | QVM149 | — | COMPLETED | 2019-07-12 | NCT03158311 |
| Novartis | QAW039 | — | COMPLETED | 2019-07-05 | NCT03226392 |
| Novartis | QAW039 | — | COMPLETED | 2019-07-04 | NCT02563067 |
| Novartis | QAW039 | — | COMPLETED | 2019-07-02 | NCT03215758 |
| GSK | FF/UMEC/VI 100/62.5/25 mcg | — | COMPLETED | 2019-06-25 | NCT03184987 |
| Novartis | QVM149 150/50/160 | — | COMPLETED | 2019-06-14 | NCT02571777 |
| AO GENERIUM | Genolar® + Symbicort® | — | COMPLETED | 2019-04-29 | NCT04607629 |
| Teva Branded Pharmaceutical Products R&D, Inc. | Fluticasone Propionate | Beta-2 adrenergic receptor/Glucocorticoid receptor | COMPLETED | 2019-04-07 | NCT02980133 |
| Sun Pharmaceutical Industries Limited | Zero-dose | — | COMPLETED | 2019-03-11 | NCT03528577 |
| GSK | FF/UMEC/VI (100/31.25/25) mcg | — | COMPLETED | 2019-02-22 | NCT02924688 |
| Xemed LLC | HXe MRI guided treatment sequence for BT | — | COMPLETED | 2018-12 | NCT01832363 |
| Novartis | Indacaterol acetate/Mometasone furoate | — | COMPLETED | 2018-11-21 | NCT02554786 |
| Novartis | QVM149 | — | COMPLETED | 2018-09-18 | NCT03100825 |
| AstraZeneca | Benralizumab | Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC] | COMPLETED | 2018-08-01 | NCT02869438 |
| Novartis | QMF149 | — | COMPLETED | 2018-07-19 | NCT03100500 |
| Actavis Inc. | Generic Budesonide/Formoterol Fumarate Dihydrate | — | COMPLETED | 2018-05-31 | NCT02495168 |
| Chiesi Farmaceutici S.p.A. | CHF 5993 200/6/12.5 µg | — | COMPLETED | 2018-05-28 | NCT02676089 |
| Chiesi Farmaceutici S.p.A. | CHF 5993 100/6/12.5 µg | — | COMPLETED | 2018-05-17 | NCT02676076 |
| Kindeva Drug Delivery | Budesonide/Formoterol fumarate dihydrate | — | COMPLETED | 2018-02-08 | NCT03015259 |
Showing 100 of 339 trials (top 100 by completion date — export for full list)
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Incyte Corporation | povorcitinib | — | RECRUITING | 2026-06-15 | NCT05851443 |
| Enveda Therapeutics | ENV-294 | — | RECRUITING | 2026-12 | NCT07301255 |
| Pfizer | PF-07275315 | — | RECRUITING | 2027-03-08 | NCT06977581 |
| Chiesi Farmaceutici S.p.A. | CHF5993 pMDI with HFA-152a | — | RECRUITING | 2027-06-03 | NCT07301736 |
| AstraZeneca | Tozorakimab | — | RECRUITING | 2027-06-24 | NCT06932263 |
| Keymed Biosciences Co.Ltd | CM512 injection | — | RECRUITING | 2027-07-21 | NCT07011524 |
| Novartis | Glycopyrronium bromide 25ug | — | RECRUITING | 2027-07-30 | NCT05222529 |
| Shanghai Novamab Biopharmaceuticals Co., Ltd. | LQ036 | — | RECRUITING | 2027-09 | NCT07589439 |
| Sanofi | Lunsekimig | — | RECRUITING | 2027-09-17 | NCT06676319 |
| Arrowhead Pharmaceuticals | ARO-RAGE | — | RECRUITING | 2027-12 | NCT07241546 |
| Oneness Biotech Co., Ltd. | FB825 | — | RECRUITING | 2027-12 | NCT05008965 |
| Longbio Pharma | LP-003 Injection | — | RECRUITING | 2027-12-28 | NCT07342803 |
| Eli Lilly | Brenipatide | — | RECRUITING | 2028-04 | NCT07219173 |
| AstraZeneca | — | — | RECRUITING | 2029-05-23 | NCT07525375 |
| Anhui Palo Alto Pharmaceuticals, Inc. | PA9159 Metered-Dose Inhaler, 120 μg per day for 28 days | — | RECRUITING | 2026-03 | NCT07324707 |
| Oneness Biotech Co., Ltd. | FB704A | — | RECRUITING | 2026-02-13 | NCT05018299 |
| Anhui Palo Alto Pharmaceuticals, Inc. | PA9159 Metered-Dose Inhaler, 60 μg per day for 28 days | — | RECRUITING | 2026-02 | NCT07326995 |
| Shanghai Mabgeek Biotech.Co.Ltd | MG-ZG122 Humanized Monoclonal Antibody Injection | — | ACTIVE NOT RECRUITING | 2026-05-26 | NCT07054034 |
| Uniquity One (UNI) | NSI-8226 | — | ACTIVE NOT RECRUITING | 2026-06-30 | NCT06496607 |
| GSK | GSK5784283 | — | ACTIVE NOT RECRUITING | 2026-07-17 | NCT06748053 |
| Sanofi | Amlitelimab | — | ACTIVE NOT RECRUITING | 2026-09-29 | NCT06033833 |
| Amgen | Rocatinlimab | — | ACTIVE NOT RECRUITING | 2026-10-19 | NCT06376045 |
| Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 610 | — | ACTIVE NOT RECRUITING | 2027-02 | NCT06680947 |
| Upstream Bio Inc. | Verekitug | — | ACTIVE NOT RECRUITING | 2027-09 | NCT06966479 |
| Jemincare | JYB1904 | — | ACTIVE NOT RECRUITING | 2025-10-31 | NCT06438757 |
| Shanghai Hengrui Pharmaceutical Co., Ltd. | SHR-1905 | — | ACTIVE NOT RECRUITING | 2025-04-30 | NCT05593250 |
| Akeso | AK139 | — | NOT YET RECRUITING | 2026-12-27 | NCT07436221 |
| Foresee Pharmaceuticals Co., Ltd. | linvemastat | — | NOT YET RECRUITING | 2027-01-01 | NCT07191535 |
| Nanjing RegeneCore Biotech Co., Ltd. | RC1416 | — | NOT YET RECRUITING | 2027-10-25 | NCT07403487 |
| Kinaset Therapeutics Inc | Frevecitinib | — | NOT YET RECRUITING | 2027-11-30 | NCT07532265 |
| Guangdong Hengrui Pharmaceutical Co., Ltd | SHR4597 | — | NOT YET RECRUITING | 2025-10 | NCT06940700 |
| Sanofi | Lunsekimig | — | COMPLETED | 2026-02-23 | NCT06102005 |
| AstraZeneca | AZD8630 | — | COMPLETED | 2026-02-04 | NCT06529419 |
| AstraZeneca | Atuliflapon | — | COMPLETED | 2026-01-07 | NCT05251259 |
| Upstream Bio Inc. | Verekitug (UPB-101) | — | COMPLETED | 2025-12-16 | NCT06196879 |
| AstraZeneca | AZD4604 | — | COMPLETED | 2025-10-28 | NCT06020014 |
| AstraZeneca | AZD4604 | — | COMPLETED | 2025-10-15 | NCT06435273 |
| Chiesi Farmaceutici S.p.A. | CHF 6001 | — | COMPLETED | 2025-08-11 | NCT06900816 |
| AstraZeneca | — | — | COMPLETED | 2025-06-04 | NCT06644924 |
| Arrowhead Pharmaceuticals | ARO-RAGE | — | COMPLETED | 2025-04-16 | NCT05276570 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | TQC2731 injection | — | COMPLETED | 2025-03-05 | NCT05472324 |
| Sanofi | Amlitelimab | — | COMPLETED | 2024-10-11 | NCT05421598 |
| Beijing Kanova Biopharmaceutical Co., LTD | XKH001 Injection | — | COMPLETED | 2024-02-20 | NCT05991661 |
| Sanofi | Rilzabrutinib | Kinase Inhibitor [EPC] | COMPLETED | 2024-02-06 | NCT05104892 |
| ARS Pharmaceuticals, Inc. | ARS-1 | — | COMPLETED | 2024-02-02 | NCT05363670 |
| Keymed Biosciences Co.Ltd | CM310 | — | COMPLETED | 2023-09-13 | NCT05186909 |
| Aquilon Pharmaceuticals S.A. | AQ001S 0.125 mg/ml | — | COMPLETED | 2022-12-31 | NCT04933383 |
| AstraZeneca | MEDI3506 | — | COMPLETED | 2022-12-12 | NCT04570657 |
| Chiesi Farmaceutici S.p.A. | Placebo 152a | — | COMPLETED | 2022-10-31 | NCT05472662 |
| Roche | MTPS9579A | — | COMPLETED | 2022-05-19 | NCT04092582 |
| Novartis | Mometasone furoate | H1 receptor | COMPLETED | 2022-04-11 | NCT04589663 |
| T-Balance Therapeutics GmbH | Tregalizumab | — | COMPLETED | 2022-01-12 | NCT04673591 |
| Tetherex Pharmaceuticals Corporation | SelK2 (Part 1) | — | COMPLETED | 2021-12-21 | NCT04540042 |
| Chemlmmune Therapeutics LLC | XC8 100 mg | — | COMPLETED | 2021-08-27 | NCT04674137 |
| Knopp Biosciences | Dexpramipexole | — | COMPLETED | 2020-12-03 | NCT04046939 |
| AstraZeneca | Tezepelumab | — | COMPLETED | 2020-11-16 | NCT03688074 |
| Theravance Biopharma | TD-8236 | — | COMPLETED | 2020-08-28 | NCT04150341 |
| GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc. | GB001 | — | COMPLETED | 2020-07-23 | NCT03683576 |
| Palobiofarma SL | PBF-680 | — | COMPLETED | 2020-02-05 | NCT03774290 |
| AstraZeneca | AZD7594 DPI 55μg/50μg. | — | COMPLETED | 2019-09-30 | NCT03622112 |
| Palobiofarma SL | PBF-680 | — | COMPLETED | 2019-09-30 | NCT02635945 |
| Novartis | Indacaterol acetate 75 μg | — | COMPLETED | 2019-06-19 | NCT02892019 |
| Chiesi Farmaceutici S.p.A. | CHF6366 | — | COMPLETED | 2019-04-16 | NCT03378648 |
| Novartis | CJM112 | — | COMPLETED | 2019-04-08 | NCT03299686 |
| Roche | MSTT1041A | — | COMPLETED | 2019-04-05 | NCT02918019 |
| Sanofi | SAR440340 | — | COMPLETED | 2019-03-21 | NCT03387852 |
| GSK | GSK3772847 | — | COMPLETED | 2019-02-15 | NCT03207243 |
| GSK | Fluticasone furoate (FF) Dry Powder Inhaler | — | COMPLETED | 2018-12-20 | NCT02991859 |
| Chiesi Farmaceutici S.p.A. | CHF 718 pMDI | — | COMPLETED | 2018-11-28 | NCT03084718 |
| AstraZeneca | AZD1419 | — | COMPLETED | 2018-09-25 | NCT02898662 |
| Concentrx Pharmaceuticals, Inc. | Halix albuterol 90 mcg | — | COMPLETED | 2018-08-31 | NCT03643874 |
| Novartis | QVM149 150/50/80 μg o.d. | — | COMPLETED | 2018-08-02 | NCT03063086 |
| Chiesi Farmaceutici S.p.A. | CHF 1531 pMDI | — | COMPLETED | 2018-07-23 | NCT03086460 |
| GSK | UMEC | — | COMPLETED | 2018-05-30 | NCT03012061 |
| Laboratorios Leti, S.L. | DP/MG/14-1 | — | COMPLETED | 2018-05 | NCT02340130 |
| AstraZeneca | AS MDI 90 μg | — | COMPLETED | 2018-03-30 | NCT03364608 |
| AstraZeneca | AS MDI | — | COMPLETED | 2018-03-26 | NCT03371459 |
| Novartis | Treatment A: Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose) | — | COMPLETED | 2018-02-24 | NCT03108027 |
| GSK | GSK2245035 Nasal Spray Solution | — | COMPLETED | 2018-02-14 | NCT02833974 |
| Novartis | Indacaterol maleate | — | COMPLETED | 2018-01-17 | NCT03257995 |
| Sanofi | Dupilumab SAR231893/REGN668 | — | COMPLETED | 2018-01-03 | NCT02573233 |
| AbbVie | risankizumab | — | COMPLETED | 2017-10-13 | NCT02443298 |
| PHARMENTERPRISES LLC | XC8 Oral Tablet | — | COMPLETED | 2017-09-27 | NCT03450434 |
| Chiesi Farmaceutici S.p.A. | CHF1535 NEXThaler | — | COMPLETED | 2017-09-19 | NCT03108534 |
| Merck | MK-1029 150 mg | — | COMPLETED | 2017-08-16 | NCT02720081 |
| AstraZeneca | Tralokinumab | Interleukin-13 Antagonist [EPC] | COMPLETED | 2017-06-21 | NCT02449473 |
| Chiesi Farmaceutici S.p.A. | CHF 1535 35/4µg NEXThaler® | — | COMPLETED | 2017-06 | NCT02787967 |
| 3-C Institute for Social Development | — | — | COMPLETED | 2017-05 | NCT02835300 |
| GSK | Fluticasone furoate (FF) (100 mcg) | — | COMPLETED | 2017-02-21 | NCT02712047 |
| RSPR Pharma AB | CRD007 | — | COMPLETED | 2017-02-21 | NCT02615080 |
| Roche | Lebrikizumab | — | COMPLETED | 2016-12-20 | NCT01987492 |
| MedImmune LLC | MEDI9929 70 mg | — | COMPLETED | 2016-12-12 | NCT02054130 |
| GSK | Mepolizumab | Interleukin-5 Antagonist [EPC] | COMPLETED | 2016-12-07 | NCT02377427 |
| Biota Pharmaceuticals, Inc. | Vapendavir | — | COMPLETED | 2016-12 | NCT02367313 |
| AstraZeneca | Interferon beta-1a Nebuliser solution 48 μg/mL | — | COMPLETED | 2016-11-24 | NCT02491684 |
| Roche | Lebrikizumab | — | COMPLETED | 2016-10-13 | NCT02099656 |
| Hvivo | PrEP-001 | — | COMPLETED | 2016-09 | NCT03296917 |
| Pearl Therapeutics, Inc. | Glycopyrronium MDI | — | COMPLETED | 2016-03-26 | NCT02433834 |
| Theron Pharmaceuticals, Inc. | TRN-157 | — | COMPLETED | 2016-03 | NCT02382510 |
| AstraZeneca | 800 μg AZD7594 once daily | — | COMPLETED | 2016-02-08 | NCT02479412 |
Showing 100 of 220 trials (top 100 by completion date — export for full list)
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| AstraZeneca | — | — | RECRUITING | 2026-10-23 | NCT07433569 |
| GSK | Salbutamol HFA-152a | — | RECRUITING | 2026-10-30 | NCT06433921 |
| Amgen | AMG 691 | — | RECRUITING | 2027-06-07 | NCT06637371 |
| Innovent Biologics (Suzhou) Co. Ltd. | IBI3002 | — | RECRUITING | 2026-04-23 | NCT06947408 |
| Apogee Therapeutics, Inc. | APG777 | — | ACTIVE NOT RECRUITING | 2026-09 | NCT06920901 |
| Generate Biomedicines | GB-0895 (SC) | — | ACTIVE NOT RECRUITING | 2027-05 | NCT07116889 |
| AJU Pharm Co., Ltd. | AJU-R713 | — | NOT YET RECRUITING | 2025-12 | NCT07231861 |
| SinoMab BioScience Ltd | SM17 | — | COMPLETED | 2026-02-03 | NCT07466940 |
| Nanjing RegeneCore Biotech Co., Ltd. | RC1416 | — | COMPLETED | 2025-09-25 | NCT06911866 |
| AstraZeneca | AZD8630 | — | COMPLETED | 2025-09-19 | NCT07065331 |
| Innovent Biologics (Suzhou) Co. Ltd. | IBI3002 | — | COMPLETED | 2025-07-22 | NCT06213844 |
| AstraZeneca | AZD8630 | — | COMPLETED | 2025-06-27 | NCT06795906 |
| GSK | HFA-152A propellant | — | COMPLETED | 2025-06-04 | NCT06702462 |
| AstraZeneca | AZD4604 | — | COMPLETED | 2025-05-29 | NCT06732882 |
| OM Pharma SA | OM-85-IN | — | COMPLETED | 2025-02-19 | NCT06486662 |
| GSK | — | — | COMPLETED | 2024-10-24 | NCT06506266 |
| GSK | Salbutamol HFA-152a | — | COMPLETED | 2024-10-18 | NCT06433908 |
| Teva Branded Pharmaceutical Products R&D, Inc. | TEV-56248 | — | COMPLETED | 2024-10-01 | NCT06290102 |
| Anhui Palo Alto Pharmaceuticals, Inc. | PA9159 Inhalation aerosol, 60 μg one day treatment | — | COMPLETED | 2024-09-12 | NCT06916273 |
| AO GENERIUM | Genolair, solution for subcutaneous administration, 150 mg | — | COMPLETED | 2024-06-09 | NCT06494345 |
| AstraZeneca | AZD4604 Inhalation Powder, 1 mg | — | COMPLETED | 2024-05-20 | NCT06157255 |
| Arrowhead Pharmaceuticals | ARO-RAGE Injection | — | COMPLETED | 2024-02-08 | NCT05533294 |
| Genrix (Shanghai) Biopharmaceutical Co., Ltd. | GR2002 injection | — | COMPLETED | 2024-01-02 | NCT05954611 |
| CSL Behring | Human beta common receptor antagonist monoclonal antibody | — | COMPLETED | 2023-11-14 | NCT04082754 |
| Harbour BioMed (Guangzhou) Co. Ltd. | HBM9378 (SKB378) Injection | — | COMPLETED | 2023-10-24 | NCT05790694 |
| GSK | Depemokimab | — | COMPLETED | 2023-10-23 | NCT05602025 |
| Chiesi Farmaceutici S.p.A. | CHF5993 | — | COMPLETED | 2023-10-13 | NCT05830071 |
| Shanghai Hengrui Pharmaceutical Co., Ltd. | SHR-1905/placebo | — | COMPLETED | 2023-10-09 | NCT04905602 |
| SinoMab BioScience Ltd | SM17 | — | COMPLETED | 2023-09-26 | NCT05332834 |
| Upstream Bio Inc. | UPB-101 | — | COMPLETED | 2023-08-15 | NCT05448651 |
| AstraZeneca | AZD8630 | — | COMPLETED | 2023-08-02 | NCT05110976 |
| Chiesi Farmaceutici S.p.A. | Test product (T):CHF 5993 BDP/FF/GB 200/6/12.5 µg pMDI | — | COMPLETED | 2023-07-14 | NCT05898984 |
| Bio-Thera Solutions | Mepolizumab Injection (BAT2606 Injection) | — | COMPLETED | 2023-05-26 | NCT05576454 |
| GSK | Salbutamol HFA-152a | — | COMPLETED | 2023-05-21 | NCT05791565 |
| Mabwell (Shanghai) Bioscience Co., Ltd. | Experimental drug 9MW1911 | — | COMPLETED | 2023-03-06 | NCT05803902 |
| Sanofi | SAR443765 | — | COMPLETED | 2023-02-24 | NCT05366764 |
| AstraZeneca | AZD4604 for inhalation via DPI | — | COMPLETED | 2023-01-24 | NCT04769869 |
| GSK | GSK3511294 | — | COMPLETED | 2022-12-23 | NCT05140200 |
| Atridia Pty Ltd. | SHR-1905 | — | COMPLETED | 2022-11-12 | NCT04800263 |
| Keymed Biosciences Co.Ltd | CM326 | — | COMPLETED | 2022-10-11 | NCT05171348 |
| AstraZeneca | Tezepelumab | — | COMPLETED | 2022-09-27 | NCT04673630 |
| Trio Medicines Ltd. | TR4 | — | COMPLETED | 2022-08-16 | NCT07272135 |
| Mabwell (Shanghai) Bioscience Co., Ltd. | 9MW1911 Injection | — | COMPLETED | 2022-07-03 | NCT05170243 |
| Evelo Biosciences, Inc. | EDP1867 | — | COMPLETED | 2022-02-28 | NCT04927195 |
| Shanghai Hengrui Pharmaceutical Co., Ltd. | SHR-1819 | — | COMPLETED | 2021-12-10 | NCT04772365 |
| TFF Pharmaceuticals, Inc. | Voriconazole Inhalation Powder | — | COMPLETED | 2021-11-12 | NCT04576325 |
| Equillium | EQ001 | — | COMPLETED | 2021-10-12 | NCT04007198 |
| Keymed Biosciences Co.Ltd | CM326 | — | COMPLETED | 2021-09-28 | NCT04842201 |
| Jiangsu HengRui Medicine Co., Ltd. | SHR-1703 | — | COMPLETED | 2021-09-21 | NCT04480762 |
| Bond Avillion 2 Development LP | BDA MDI (PT027) 160/180 μg | — | COMPLETED | 2021-07-05 | NCT04848662 |
| AstraZeneca | AZD0449 | — | COMPLETED | 2021-06-24 | NCT03766399 |
| Taizhou Mabtech Pharmaceutical Co.,Ltd | Omalizumab | Anti-IgE [EPC] | COMPLETED | 2021-04-26 | NCT04778137 |
| GSK | melrilimab (GSK3772847) 70 milligram (mg) | — | COMPLETED | 2020-12-21 | NCT04366349 |
| KoBioLabs | KBL693 | — | COMPLETED | 2020-10-30 | NCT04307173 |
| Boehringer Ingelheim | BI 894416 | — | COMPLETED | 2020-10-26 | NCT03971539 |
| Pieris Australia Pty Ltd | PRS-060 | — | COMPLETED | 2020-09-15 | NCT03574805 |
| Theravance Biopharma | TD-8236 | — | COMPLETED | 2020-07-13 | NCT03652038 |
| AstraZeneca | AZD7594 | — | COMPLETED | 2020-07-09 | NCT03976869 |
| AstraZeneca | Tezepelumab | — | COMPLETED | 2019-12-30 | NCT03989544 |
| AstraZeneca | AZD7594 | — | COMPLETED | 2019-11-28 | NCT04072562 |
| Chiesi Farmaceutici S.p.A. | Treatment A | — | COMPLETED | 2019-11-22 | NCT03942666 |
| GSK | GSK3511294 | — | COMPLETED | 2019-07-31 | NCT03287310 |
| AstraZeneca | AZD8154 | — | COMPLETED | 2019-07-29 | NCT03436316 |
| Chiesi Farmaceutici S.p.A. | Therapeutic Dose 1 | — | COMPLETED | 2019-07-24 | NCT03859414 |
| Novartis | CSJ117 | — | COMPLETED | 2019-07-16 | NCT03138811 |
| AstraZeneca | Intravenous Infusion | — | COMPLETED | 2019-07-05 | NCT04002427 |
| AstraZeneca | AZD1402 | — | COMPLETED | 2019-06-13 | NCT03921268 |
| Sunshine Lake Pharma Co., Ltd. | Litapiprant Tablet | — | COMPLETED | 2019-01-30 | NCT03663686 |
| Regeneron | REGN3500 | — | COMPLETED | 2018-08-30 | NCT02999711 |
| Pulmatrix Inc. | Itraconazole Powder | — | COMPLETED | 2018-06-28 | NCT03479411 |
| Concentrx Pharmaceuticals, Inc. | Albuterol DPI 90mcg | — | COMPLETED | 2018-05-28 | NCT03373409 |
| Boehringer Ingelheim | BI 443651 | — | COMPLETED | 2018-02-07 | NCT03135899 |
| Peptinnovate | PIN201104 | — | COMPLETED | 2018-01 | NCT03058458 |
| Orion Corporation, Orion Pharma | salmeterol-fluticasone | — | COMPLETED | 2017-12-19 | NCT03238482 |
| Intech Biopharm Ltd. | Budesonide | Corticosteroid [EPC] | COMPLETED | 2017-11-17 | NCT04494321 |
| AstraZeneca | Abediterol | — | COMPLETED | 2017-11-09 | NCT03273127 |
| GSK | GSK2292767 50 μg | — | COMPLETED | 2017-08-11 | NCT03045887 |
| AstraZeneca | Benralizumab | Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC] | COMPLETED | 2017-07-13 | NCT02968914 |
| Vectura Limited | — | — | COMPLETED | 2017-05-22 | NCT04032834 |
| EURRUS Biotech GmbH | XC8 (histamine glutarimide) | — | COMPLETED | 2017-05 | NCT02882217 |
| AstraZeneca | Abediterol | — | COMPLETED | 2017-04-06 | NCT02967159 |
| Chiesi Farmaceutici S.p.A. | Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium | — | COMPLETED | 2017-03-21 | NCT02975843 |
| Johnson & Johnson | Part 1: CNTO 7160 | — | COMPLETED | 2017-03-16 | NCT02345928 |
| AstraZeneca | Abediterol 0.156 μg | — | COMPLETED | 2016-11-29 | NCT02777827 |
| Orion Corporation, Orion Pharma | Salmeterol/fluticasone Easyhaler | — | COMPLETED | 2016-11 | NCT03060044 |
| Zambon SpA | Z7200 without oral activated charcoal | — | COMPLETED | 2016-07 | NCT02631941 |
| AstraZeneca | AZD7594 Solution for infusion (150 μg intravenous formulation) | — | COMPLETED | 2016-06-01 | NCT02648438 |
| Teva Branded Pharmaceutical Products R&D, Inc. | Fluticasone Propionate MDPI | — | COMPLETED | 2016-06 | NCT02680561 |
| MedImmune LLC | MEDI9929, 140 mg | — | COMPLETED | 2016-05-17 | NCT02512900 |
| Intech Biopharm Ltd. | Budesonide | Corticosteroid [EPC] | COMPLETED | 2016-05 | NCT02850484 |
| AstraZeneca | AZD7594 inhalation powder (200 μg) | — | COMPLETED | 2016-04-17 | NCT02645253 |
| Vectura Limited | VR942 delivered via a Vectura Dry Powder Inhaler | — | COMPLETED | 2016-04 | NCT02473939 |
| Orion Corporation, Orion Pharma | Budesonide/formoterol | — | COMPLETED | 2016-03 | NCT03073057 |
| Amgen | AMG 282 | — | COMPLETED | 2016-03 | NCT01928368 |
| Acorda Therapeutics | CVT-301 (levodopa inhalation powder) | — | COMPLETED | 2016-03 | NCT02633007 |
| Merck | RV16UB | — | COMPLETED | 2015-12-25 | NCT01866306 |
| Orion Corporation, Orion Pharma | Salmeterol/fluticasone Easyhaler | — | COMPLETED | 2015-09 | NCT02162485 |
| PHARMENTERPRISES LLC | XC8 | — | COMPLETED | 2015-07-07 | NCT03441815 |
| Teva Branded Pharmaceutical Products R&D, Inc. | Treatment A: Fp MDPI | — | COMPLETED | 2015-07 | NCT02437604 |
| Boehringer Ingelheim | BI 1060469 Healthy | — | COMPLETED | 2015-07 | NCT02126865 |
Reformulations (23 drugs) Click to expand
Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.
AIRSUPRA
AstraZeneca
T4 2023
DEXYCU KIT
EYEPOINT PHARMS
T5 2018
TRELEGY ELLIPTA
GSK
T5 2017
QVAR REDIHALER
NORTON WATERFORD
T5 2017
AIRDUO RESPICLICK
Teva
T4 2017
SPIRIVA RESPIMAT
Boehringer Ingelheim
T3 2014
ARNUITY ELLIPTA
GSK
T5 2014
ASMANEX HFA
Merck
T2/3 2014
DULERA
Merck
T4 2010
ALVESCO
COVIS
T3 2008
SYMBICORT
AstraZeneca
T4 2006
PULMICORT FLEXHALER
CHEPLAPHARM
T5 2006
ADVAIR HFA
GSK
T3 2006
FLOVENT HFA
GSK
T3 2004
PULMICORT RESPULES
AstraZeneca
T3 2000
SINGULAIR
Merck
T1 1998
ACCOLATE
STRIDES PHARMA INTL
T1 1996
PEDIAPRED
PAI HOLDINGS
T3 1986
CELESTONE SOLUSPAN
Merck
T1 1965
KENALOG-40
APOTHECON
T5 1965
DEPO-MEDROL
Pfizer
T2 1959
SOLU-MEDROL
PHARMACIA AND UPJOHN
T2 1959
SOLU-CORTEF
PHARMACIA AND UPJOHN
T2 1955
Drug Targets
Generic Drugs (10 ANDA approved) Click to expand
Generic drugs contain the same active ingredient as the brand-name drug and are approved via ANDA (Abbreviated New Drug Application).
BECLOMETHASONE DIPROPIONATE
AMNEAL IRELAND LTD
BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE
Hikma
BREYNA
Viatris
DEXAMETHASONE
Sun Pharma
DEXAMETHASONE INTENSOL
Hikma
METHYLPREDNISOLONE ACETATE
WATSON LABS
TERBUTALINE SULFATE
EPIC PHARMA LLC
THEO-24
ENDO OPERATIONS
WIXELA INHUB
Viatris
ZAFIRLUKAST
Dr. Reddy's
Drug Categories:
- Novel Drugs: NDA Type 1/2 (new molecular entity) or original BLA
- Reformulations: NDA Type 3/5 (new dosage form of existing molecule)
- Biosimilars: BLA-approved biologics highly similar to reference products
- Generics: ANDA-approved copies of small molecule drugs